Johnson & Johnson

NYSE:JNJ

Drug Manufacturers - General

Healthcare
$272.70 -1.96%

-$4.59 today

Market cap
$656.47B
Beta
0.26
P/E (TTM)
26.7
EPS (TTM)
$8.60
Dividend yield
2.28%
52W Low $149.04High $251.71

Volume 7.93M

Average 7.71M

JNJ Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Johnson & JohnsonNYSE: JNJ

Depreciation & Amortization · Q3 FY2026 · quarter ended Sep 2026

Depreciation & amortization growth accelerates

Q3 FY2026 depreciation & amortization of $2.12B rose 19.1% year over year, ahead of the +9.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 8.1% from the prior quarter. Over 3 fiscal years it compounded at +2.5% a year.

Context

  • Depreciation & amortization amounted to 8.0% of revenue in FY2025, down 0.3 pp from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +19.1% holds above the trailing-twelve-month pace of +9.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$2.12B+8.1% QoQ
Last fiscal yearDec 2025
$7.5B+2.2% YoY
LTMSep 2026
$8.09B+9.5% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+19.1%——
1 year+2.2%——
3-year CAGR+2.5%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
7.5B USD
Year-over-year change
+2.2%
4-year CAGR
+0.4%

Depreciation & Amortization vs competitors

How JNJ compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +9.5% is the 4th highest of 11, against a peer median of -3.9%.
  • Depreciation & amortization amounts to 8.1% of revenue for JNJ, versus a peer median of 10.2%.
JNJ Competitors
Depreciation & Amortization for JNJ and competitors
Company Period LTM YoY 3-year CAGR% of revenue
JNJJohnson & JohnsonLTM Sep 2026$8.09B USD+9.5%+2.5%8.1%
ABBVAbbVie Inc.LTM Jun 2026$7.87B USD-4.8%-1.3%12.2%
MRKMerck & Co., Inc.LTM Jun 2026$6.72B USD+45.9%+14.3%10.1%
PFEPfizer Inc.LTM Jun 2026$6.58B USD-3.0%+9.2%10.3%
AZNAstraZeneca PLCLTM Sep 2026$6.41B USD+29.8%+3.0%10.3%
SNYSanofiLTM Jun 2026€5.88B EUR+22.9%+22.2%12.0%
NVSNovartis AGLTM Jun 2026$5.34B USD-11.0%-7.2%9.6%
AMGNAmgen Inc.LTM Jun 2026$4.67B USD-15.5%+14.8%12.2%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$3.18B USD-51.1%-26.9%6.5%
GILDGilead Sciences, Inc.LTM Jun 2026$2.76B USD-0.4%+9.5%9.1%
GSKGSK plcLTM Jun 2026£2.21B GBP-34.0%+2.5%6.7%
Peer median (excluding JNJ) —-3.9%+6.1%10.2%

Competitors are the stored peer set for JNJ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Jan 2022
FY2022
Jan 2023
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income20.88B17.94B13.33B14.07B26.8B
Depreciation & Amortization7.39B6.97B7.49B7.34B7.5B
Deferred Income Tax(2.08B)(1.66B)(4.19B)(2.18B)1.54B
Stock-Based Compensation1.14B1.14B1.16B1.18B1.35B
Change in Working Capital(4.24B)(4.01B)2.51B1.84B(12.72B)
Accounts Receivables(2.4B)(1.29B)(624M)(406M)(1.78B)
Inventory(1.25B)(2.53B)(1.32B)(1.13B)(1.45B)
Accounts Payables2.44B1.1B2.35B1.62B2.38B
Other Working Capital(3.03B)(1.29B)2.11B1.75B(11.86B)
Other Non-Cash Items324M819M2.5B2.03B49M
Operating Cash Flow23.41B21.19B22.79B24.27B24.53B
Capital Expenditures(3.65B)(4.01B)(4.54B)(4.42B)(4.83B)
Acquisitions (Net)(60M)(17.65B)358M(15.15B)(17.54B)
Purchases of Investments(30.39B)(32.38B)(10.91B)(1.73B)(920M)
Sales of Investments25.01B41.61B19.39B2.46B1.66B
Other Investing Activities417M65M(3.42B)235M(1.96B)
Investing Cash Flow(8.68B)(12.37B)878M(18.6B)(23.59B)
Debt Repayment(990M)7.45B(2.73B)10.05B9.64B
Common Stock Issued004.24B00
Common Stock Repurchased(3.46B)(6.04B)(5.05B)(2.43B)(5.95B)
Dividends Paid(11.03B)(11.68B)(11.77B)(11.82B)(12.38B)
Other Financing Activities1.43B1.39B(508M)1.07B3.16B
Financing Cash Flow(14.05B)(8.87B)(15.83B)(3.13B)(5.54B)
Effect of Forex Changes(178M)(312M)(112M)(289M)201M
Net Change in Cash502M(360M)7.73B2.25B(4.4B)
Free Cash Flow19.76B17.19B18.25B19.84B19.7B

Johnson & Johnson

NYSE:JNJ

Intrinsic Alpha fair value

Locked

Current Price

$272.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.